Diagnosed with Relapsing Multiple Sclerosis?
Consider joining the ENSURE clinical study


About the ENSURE Study
The ENSURE study is a clinical study of a potential new oral study drug for patients diagnosed with relapsing multiple sclerosis (RMS), a chronic disease affecting the brain and spinal cord. Patients with multiple sclerosis can experience a variety of symptoms, including problems with vision, bladder control, arm or leg movement, sensation or balance. Relapsing MS is characterized by attacks, also called relapses, meaning new or worsening of symptoms, lasting for at least 24 hours before full or partial recovery.
The purpose of the ENSURE study is to investigate how well the oral study drug works and how safe it is in patients with RMS. The study will be conducted at around 100 medical sites worldwide and 1050 patients are planned to take part in this clinical study.
Who Can Participate?
Short Study Summary
Medical Condition:
Study Duration:
Phase:
What are the Next Steps if I am Interested to Participate in the ENSURE Study?
There are other criteria that need to be fulfilled to be able to take part in the ENSURE study.
If you decide you want to join the ENSURE study and if your study doctor confirms that you could be a good match, you will be asked to visit the study clinic for a screening visit. During this visit, you will be asked to read the study information and sign an informed consent form before any procedures are performed.
Additional tests will be performed to determine if your qualify to participate in the study.
To find out if the study may be suitable for you, please click the button:
STEP 1
Answer some questions about your RMS to ensure that this study is right for you.
STEP 2
A nurse will get in touch with you on the phone to ask some additional questions about your RMS.
STEP 3
You will be contacted by the study clinic to schedule a screening visit.
What Does It Mean to Participate in the ENSURE Study?
about
1.5 years
Main treatment period
up to
8 years
Extended treatment period
You will need to return to the study site after 4 weeks, and then every 24 weeks for up to 8 years to be evaluated. Your participation is completely voluntary. You can choose to leave at any time without any further explanation and without any impact on your future care.

For additional information about clinical studies in general please see the FAQ-section